| 1 |
AACR LBx 24 – Development of a scoring system to classify HER2 protein expression in Circulating Tumour Cells through immunofluorescence following isolation using Parsortix® instruments |
通过免疫荧光结合Parsortix®仪器分离，开发一种评分系统以分类循环肿瘤细胞中的HER2蛋白表达 |
AACR LBx Conference 2024 |
| 2 |
AACR LBx 24 – Investigating PDL-1 status in Circulating Tumour Cells isolated from the blood samples of lung cancer patients |
调查从肺癌患者血液样本中分离出的循环肿瘤细胞中的PDL-1状态 |
AACR LBx Conference 2024 |
| 3 |
EACR LBx 24 – Enhancing Multiplexing Capabilities in Digital PCR for Circulating Tumour Cell Analysis Using Amplitude-Based Methodology |
使用基于幅度的方法增强数字PCR中循环肿瘤细胞分析的多重能力 |
EACR LBx Conference 2024 |
| 4 |
EACR LBx 24 – Combined epitope-independent microfluidic isolation and advanced staining of circulating tumour cells isolated from metastatic prostate cancer blood samples |
结合表位非依赖微流控分离和进阶染色，从转移性前列腺癌血样中分离循环肿瘤细胞 |
EACR LBx Conference 2024 |
| 5 |
DDR Conference – Detection of DNA Damage Response Biomarkers in Circulating Tumour Cells using ANGLE’s Parsortix® instrument and downstream immunofluorescence assays |
使用ANGLE的Parsortix®仪器和下游免疫荧光分析检测循环肿瘤细胞中的DNA损伤反应生物标志物 |
September 2024 |
| 6 |
Targeted Sequencing of Circulating Tumour Cells Captured by Parsortix System Enables Low Frequency Variant Analysis with VarMapTM Pan-Cancer NGS Panel |
使用Parsortix系统捕获的循环肿瘤细胞的靶向测序支持使用VarMapTM泛癌NGS面板进行低频变体分析 |
June 2024 |
| 7 |
Detection of DNA damage in circulating tumour cells harvested from blood samples of ovarian and prostate cancer patients |
从卵巢癌和前列腺癌患者血样中收集的循环肿瘤细胞中检测DNA损伤 |
June 2024 |
| 8 |
Development and analytical validation of a novel assay for HER2 assessment on circulating tumour cells using Parsortix® isolation and BioView imaging technologies |
开发并分析验证一种结合Parsortix®分离和BioView成像技术的新型循环肿瘤细胞HER2评估方法 |
April 2024 |
| 9 |
CellKeepTM slide enhances retention of circulating tumour cells harvested from patient blood samples using the Parsortix® system |
CellKeepTM载玻片通过Parsortix®系统从患者血样中采集的循环肿瘤细胞增强保留 |
May 2024 |
| 10 |
Integrating isolation using label-independent microfluidics and advanced staining for comprehensive Circulating Tumour Cell Analysis |
结合使用不依赖标记微流控和进阶染色进行全面循环肿瘤细胞分析 |
March 2024 |
| 11 |
Interrogating HER2 status in Circulating Tumor Cells isolated using the Parsortix® System from Metastatic Breast Cancer patients |
使用Parsortix®系统从转移性乳腺癌患者中分离的循环肿瘤细胞研究HER2状态 |
March 2024 |
| 12 |
Circulating Tumour Cell Analysis to Evaluate Docetaxel Treatment Response and Resistance Markers in Prostate Cancer |
循环肿瘤细胞分析用于评估前列腺癌中多西他赛治疗的反应和耐药标志物 |
May 2023 |
| 13 |
Detection and molecular characterization of EpCAM positive and EpCAM negative circulating tumor cells isolated from SCLC patients using an epitope independent platform |
使用表位非依赖平台分离的小细胞肺癌患者中的EpCAM阳性和阴性循环肿瘤细胞检测与分子表征 |
May 2023 |
| 14 |
Integration of RNA and DNA blood-borne cancer biomarkers |
RNA和DNA血液癌症生物标志物的整合 |
May 2023 |
| 15 |
Evaluation of HER2 status in circulating tumour cells isolated using ANGLE’s Parsortix®System |
使用ANGLE的Parsortix®系统分离的循环肿瘤细胞的HER2状态评估 |
April 2023 |
| 16 |
Detection of DNA Damage in Circulating Tumor Cells Isolated using the Parsortix®System |
使用Parsortix®系统分离的循环肿瘤细胞中的DNA损伤检测 |
March 2023 |
| 17 |
Identification of circulating tumor cells captured by the FDA cleared Parsortix®PC1 System from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations |
使用FDA批准的Parsortix®PC1系统从转移性乳腺癌患者外周血中捕获循环肿瘤细胞并进行免疫荧光与细胞病理评估 |
December 2022 |
| 18 |
A Multi-center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix®PC1 System in support of FDA clearance |
一项支持FDA批准的多中心临床研究，用于从转移性乳腺癌患者中收集和表征循环肿瘤细胞 |
December 2022 |
| 19 |
Maximizing clinical utility of liquid biopsy utilizing a single blood sample for ctDNA and CTC analysis using the Parsortix®System |
使用Parsortix®系统通过单次血液样本进行ctDNA和CTC分析以最大化液体活检的临床效用 |
October 2022 |
| 20 |
Morphological Characteristics of Malignancy in Circulating Tumor Cells |
循环肿瘤细胞中恶性特征的形态学研究 |
September 2022 |
| 21 |
Antigen-independent enrichment of circulating tumour cells in metastatic breast and ovarian cancer |
转移性乳腺癌和卵巢癌中循环肿瘤细胞的抗原非依赖富集 |
May 2022 |
| 22 |
Epithelial and Mesenchymal CTC Detection in Triple Negative Breast Cancer Patients using ANGLE’s Parsortix®System |
使用ANGLE的Parsortix®系统检测三阴性乳腺癌患者中的上皮和间质CTC |
April 2022 |
| 23 |
Circulating Tumour Cell Analysis to Evaluate Docetaxel Treatment Response and Resistance Markers in Prostate Cancer |
循环肿瘤细胞分析用于评估前列腺癌中多西他赛治疗的反应和耐药标志物 |
November 2021 |
| 24 |
Detection of circulating tumor cells in platinum-resistant ovarian cancer patients enrolled in the GANNET53 study |
在GANNET53研究中检测铂类耐药卵巢癌患者的循环肿瘤细胞 |
September 2021 |
| 25 |
Molecular characterization of circulating tumor cells enriched by a microfluidic platform in patients with non-small cell lung cancer |
在非小细胞肺癌患者中通过微流控平台富集的循环肿瘤细胞的分子表征 |
September 2021 |
| 26 |
Detection of p53 aggregates in circulating tumour cells of patients with small cell lung cancer |
在小细胞肺癌患者的循环肿瘤细胞中检测p53聚集体 |
September 2021 |
| 27 |
Mesenchymal markers: the new avenue for circulating tumor cells detection |
间质标志物：循环肿瘤细胞检测的新方向 |
April - May 2021 |
| 28 |
Investigation of PD-L1 expression in circulating tumor cells isolated using the Parsortix®system in metastatic lung and breast cancer patients |
使用Parsortix®系统从转移性肺癌和乳腺癌患者中分离的循环肿瘤细胞中研究PD-L1表达 |
April - May 2021 |
| 29 |
Isolation of ovarian cancer circulating tumor cells using an epitope independent microfluidic cell capture device and their interrogation using a multiplex gene expression assay or immunofluorescence |
使用表位非依赖的微流控细胞捕获设备分离卵巢癌循环肿瘤细胞并使用多重基因表达分析或免疫荧光对其研究 |
March 2020 |
| 30 |
Molecular characterisation of circulating tumor cells in head and neck squamous cell carcinoma: Direct comparison of a label-independent size-based microfluidic device with EpCAM-based CTC enrichment |
头颈部鳞状细胞癌中循环肿瘤细胞的分子表征：不依赖标记大小微流控设备与基于EpCAM的CTC富集的直接比较 |
March - April 2019 |
| 31 |
Molecular characterization of circulating tumor cells in cholangiocarcinoma patients: A new tool for treatment management? |
胆管癌患者循环肿瘤细胞的分子表征：治疗管理的新工具？ |
March - April 2019 |
| 32 |
Increased chromatin heterogeneity in circulating tumor cells (CTCs) is associated with high levels of HER2 expression in metastatic breast cancer (MBC) |
循环肿瘤细胞（CTCs）中的染色质异质性增加与转移性乳腺癌（MBC）中HER2高表达相关 |
March - April 2019 |
| 33 |
Detection of CK-19 mRNA positive CTCs, isolated with a size-based microfluidics platform, in NSCLC patients under osimertinib therapy |
在接受奥希替尼治疗的NSCLC患者中，检测使用基于大小的微流控平台分离的CK-19 mRNA阳性CTCs |
March - April 2019 |
| 34 |
Parsortix®system: Analytic performance evaluation using ovarian cancer cell lines |
Parsortix®系统：使用卵巢癌细胞系进行的分析性能评估 |
March - April 2019 |
| 35 |
Multiplex gene expression using the HyCEAD assay in CTCs isolated with the Parsortix®system |
在使用Parsortix®系统分离的CTCs中使用HyCEAD检测进行多重基因表达分析 |
March - April 2019 |
| 36 |
A novel method to enrich and characterize circulating fetal cells using the Parsortix®cell separation system |
使用Parsortix®细胞分离系统富集和表征循环胎儿细胞的新方法 |
October 2018 |
| 37 |
CTCs in Prostate Cancer: Molecular Characterization, Immunostaining and Enumeration by Combination of Label-free Parsortix®CTC Enrichment and AdnaTest Prostate Cancer Panel Expression Profiling for PSMA, AR and AR-V7 |
前列腺癌中的CTCs：通过结合无标记Parsortix®CTC富集和AdnaTest前列腺癌面板表达分析进行分子表征、免疫染色和计数 |
May 2018 |
| 38 |
A novel ex vivo culture workflow to enrich and expand circulating tumor cells (CTCs) from patients with Stage III/IV Breast Cancer |
一种新的体外培养工作流程，用于从III/IV期乳腺癌患者中富集和扩增循环肿瘤细胞（CTCs） |
April 2018 |
| 39 |
A fast and sensitive workflow to screen therapy-relevant mutations in circulating tumor cells and quantification of cancer-associated exosomal mRNA in plasma of cancer patients |
一种快速敏感的工作流程，用于筛查循环肿瘤细胞中的治疗相关突变，并量化癌症患者血浆中的癌症相关外泌体mRNA |
April 2018 |
| 40 |
Ember Trial: Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting with a Pelvic Mass |
Ember试验：评估多种蛋白质和分子生物标志物，以估算骨盆肿块妇科患者的癌症风险 |
March 2018 |
| 41 |
The whole transcriptional landscape of circulating tumor cells compared to metastases in stage IV breast cancer |
IV期乳腺癌中循环肿瘤细胞与转移灶的全转录图谱对比 |
December 2017 |
| 42 |
Highly Multiplexed Molecular Analysis of Circulating Tumor Cells Enriched Using the Epitope Independent Parsortix®System |
使用表位非依赖Parsortix®系统富集的循环肿瘤细胞的高度多重分子分析 |
November 2017 |
| 43 |
Establishment and evaluation of a novel method for the size separation of disseminated tumor cells from cancer patient bone marrow by a microfluidic platform |
通过微流控平台建立和评估从癌症患者骨髓中分离扩散性肿瘤细胞的新方法 |
October 2017 |
| 44 |
Parsortix®system enables isolation of viable CTCs from leukapheresis product with subsequent culture |
Parsortix®系统支持从白细胞单采产品中分离活性CTCs并进行后续培养 |
October 2017 |
| 45 |
The novel association of circulating tumour cells and circulating megakaryocytes with prostate cancer prognosis |
循环肿瘤细胞和循环巨核细胞与前列腺癌预后的新型关联 |
October 2017 |
| 46 |
Single CTC isolation for genetic analysis using Parsortix®and VyCAP |
使用Parsortix®和VyCAP进行遗传分析的单个CTC分离 |
October 2017 |
| 47 |
Antibody-free microfluidics-based circulating tumor cell enrichment by Parsortix®and downstream molecular characterization by Quantigene branched DNA technology |
基于Parsortix®的无抗体微流控循环肿瘤细胞富集及后续Quantigene分支DNA技术分子表征 |
August 2016 |
| 48 |
Surface marker independent enrichment of circulating or disseminated cancer cells from blood or lymph nodes using a micro-fluidic device |
使用微流控设备从血液或淋巴结中富集表面标记物非依赖的循环或扩散癌细胞 |
July 2016 |
| 49 |
A highly sensitive method for circulating tumor cell antigen quantification in liquid biopsy |
一种高灵敏度的循环肿瘤细胞抗原定量液体活检方法 |
July 2016 |
| 50 |
Combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancer |
胰腺癌患者血液中的循环肿瘤细胞（CTC）和循环肿瘤DNA（ctDNA）联合分析 |
April 2016 |
| 51 |
The combination of Parsortix®system and CellCelector™ micromanipulator enables the characterization of EpCAM negative circulating tumor cells in breast cancer |
Parsortix®系统与CellCelector™微操作器结合，支持乳腺癌EpCAM阴性循环肿瘤细胞的表征 |
March 2016 |
| 52 |
Circulating rare cells enable highly efficient cancer detection |
循环稀有细胞支持高效癌症检测 |
September 2015 |
| 53 |
Intra-tumor heterogeneity in prostate cancer and the implication in CTC analysis |
前列腺癌中的肿瘤内异质性及其在CTC分析中的意义 |
June 2015 |
| 54 |
Circulating rare cells enable highly efficient cancer detection |
循环稀有细胞支持高效癌症检测 |
April 2015 |
| 55 |
Enrichment and isolation of uncontaminated breast cancer cells from human blood samples |
从人类血液样本中富集和分离未受污染的乳腺癌细胞 |
April 2015 |
| 56 |
Evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumor cells |
一种新型微流控设备在表位非依赖循环肿瘤细胞富集中的评估 |
November 2014 |
| 57 |
Technical validation of a novel label-independent device to capture CTCs |
一种新型不依赖标记装置捕获CTCs的技术验证 |
October 2014 |